MARK2 and acute myeloid leukemia: CK1α, a serine/threonine protein kinase, is a viable target for AML therapy for promoting AML progression by inhibiting p53 pathways.310 Research by Woo et al. promoted the development of an IKZF2 degrader, which emerged as a dual degrader of IKZF2 and CK1α through unbiased proteomics and PRISM screening assays.